Display:
Providers:
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Yesterday's News, March 01, 2021 | ||
---|---|---|
February 26, 2021 | ||
February 25, 2021 | ||
February 24, 2021 | ||
February 23, 2021 | ||
February 22, 2021 | ||
February 18, 2021 | ||
February 16, 2021 | ||
February 15, 2021 | ||
February 12, 2021 | ||
February 11, 2021 | ||
February 10, 2021 | ||
February 09, 2021 | ||
Next > |
Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.
Copyright © 2021. All rights reserved.